Biotech Values

[DewDiligence]

ENTA/(ASMB)—[Vemlidy] seems like a high barrier to overcome relative to edp-514 preclinical results.

The goal of ENTA's EDP-514 program isn’t to outperform nukes as monotherapy, but rather to see if adding a core inhibitor to a nuke can clear the viral infection, which nuke monotherapy almost never does.